deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02841033

Daratumumab for the Treatment of Patients With AL Amyloidosis

A Phase I-II Trial of Daratumumab for the Treatment of Patients With AL Amyloidosis

Sponsor: Boston Medical Center

Conditions AL Amyloidosis
Interventions daratumumab
Updated 16 times since 2017 Last updated: Apr 15, 2021 Started: Mar 20, 2017 Primary completion: May 28, 2020 Completion: Jul 17, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates AL Amyloidosis and is currently completed. Boston Medical Center leads this study, which shows 16 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jun 2018 · 14 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Jun 2019 · 9 months · monthly snapshot~Jun 2019 – ~Oct 2019 · 4 months · monthly snapshot~Oct 2019 – ~Mar 2020 · 5 months · monthly snapshot~Mar 2020 – ~Aug 2020 · 5 months · monthly snapshot~Aug 2020 – ~Dec 2020 · 4 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Dec 2022 · 18 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE1_PHASE2

  5. Jun 2021 — Dec 2022 [monthly]

    Completed PHASE1_PHASE2

▶ Show 11 earlier versions

  1. Jan 2021 — Jun 2021 [monthly]

    Completed PHASE1_PHASE2

  2. Dec 2020 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  3. Aug 2020 — Dec 2020 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  4. Mar 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Oct 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Jun 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Sep 2018 — Jun 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  8. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE1_PHASE2

  9. Apr 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  10. Feb 2017 — Apr 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  11. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Boston Medical Center
  • Janssen Pharmaceuticals
Data source: Boston Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations